This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Naptumomab estafenatox
DrugBank Accession Number
DB12807
Background

Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Naptumomab Estafenatox
External IDs
  • ABR-217620

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Naptumomab estafenatox.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Naptumomab estafenatox.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Naptumomab estafenatox.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naptumomab estafenatox.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Naptumomab estafenatox.
AmivantamabThe risk or severity of adverse effects can be increased when Naptumomab estafenatox is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Naptumomab estafenatox.
AnsuvimabThe risk or severity of adverse effects can be increased when Naptumomab estafenatox is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Naptumomab estafenatox.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Naptumomab estafenatox.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
93T929W6LC
CAS number
676258-98-3

References

General References
Not Available
PubChem Substance
347911384
Wikipedia
Naptumomab_estafenatox

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2, 3CompletedTreatmentRenal Cell Carcinoma1
1CompletedTreatmentMalignant Neoplasm of Pancreas / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Carcinoma1
1CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentAdenocarcinomas of the Pancreas / Bladder Cancer, Cancer / Cervical Squamous Cell Carcinoma / Endometrial Cancer / ER+ Breast Cancer / Gastroesophageal Cancer (GC) / Hepatocellular Carcinoma / HER 2 Negative Breast Cancer / Melanoma / Mesotheliomas / Metastatic Colorectal Cancer (CRC) / Non-Small Cell Lung Carcinoma (NSCLC) / NSCL2 Gene Mutation / Ovarian Cancer / Prostate Cancer / Renal Cell Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Triple Negative Breast Cancer / Urothelial Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 21, 2016 00:23 / Updated at February 24, 2021 23:07